Published in Eur J Clin Pharmacol on July 28, 2010
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics (2012) 1.25
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J (2012) 0.97
CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol (2012) 0.96
Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective. Indian J Med Res (2014) 0.96
Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine. Front Genet (2013) 0.88
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol (2015) 0.85
Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J (2015) 0.85
Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J (2011) 0.84
Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy. Int J Med Sci (2013) 0.84
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics (2013) 0.80
Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population. Daru (2014) 0.79
Regulatory polymorphisms in CYP2C19 affecting hepatic expression. Drug Metabol Drug Interact (2013) 0.78
Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population. Med J Islam Repub Iran (2015) 0.77
Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent. Eur J Clin Pharmacol (2010) 0.77
Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. Eur J Clin Pharmacol (2012) 0.77
CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics Pers Med (2017) 0.75
Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects. AAPS J (2013) 0.75
Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors. Meta Gene (2016) 0.75
Association of CYP2C9 Genetic Variants with Vitiligo. Ann Dermatol (2014) 0.75
CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy. Eur J Clin Pharmacol (2015) 0.75
Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. Pharmacogenet Genomics (2017) 0.75
Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (2004) 125.23
A new statistical method for haplotype reconstruction from population data. Am J Hum Genet (2001) 59.30
Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet (2005) 14.09
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation (2010) 3.68
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther (2007) 3.35
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol (1998) 3.17
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther (2006) 3.09
A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet (2004) 2.44
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol (2001) 2.38
Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics (1994) 2.32
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics (2001) 1.83
Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther (1989) 1.55
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther (2005) 1.51
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.50
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol (2008) 1.48
Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther (2007) 1.43
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J (2010) 1.33
Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry (1991) 1.18
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun (2002) 1.15
Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics (2004) 1.14
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol (2008) 1.08
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol (2008) 1.08
CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat (2008) 1.00
Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics (2009) 0.99
Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol (2005) 0.95
Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol (2010) 0.94
Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10. Nat Genet (2005) 0.93
Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics (1994) 0.88
Oxidation of endobiotics mediated by xenobiotic-metabolizing forms of human cytochrome. Curr Drug Metab (2009) 0.87
CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol (2010) 0.86
Cytochrome P450 2C19 genetic polymorphisms in Ugandans. Eur J Clin Pharmacol (2008) 0.82
Association studies of estrogen receptor polymorphisms in a Norwegian testicular cancer population. Cancer Epidemiol Biomarkers Prev (1995) 0.79
Cytochrome P4502C9 (CYP2C9) genotypes in a Nordic population in Denmark. Basic Clin Pharmacol Toxicol (2004) 0.76
Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients. Pharmacogenetics (1998) 0.75
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther (2007) 3.35
Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res (2009) 3.09
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther (2006) 3.09
Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr (2004) 3.01
Pharmacogenomics and individualized drug therapy. Annu Rev Med (2006) 2.95
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One (2011) 2.70
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
Serum concentrations of antibodies against vaccine toxoids in children exposed perinatally to immunotoxicants. Environ Health Perspect (2010) 2.26
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat (2011) 2.23
Delayed brainstem auditory evoked potential latencies in 14-year-old children exposed to methylmercury. J Pediatr (2004) 2.20
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol (2014) 2.14
Reduced antibody responses to vaccinations in children exposed to polychlorinated biphenyls. PLoS Med (2006) 1.97
Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol (2010) 1.96
Birth weight and prenatal exposure to polychlorinated biphenyls (PCBs) and dichlorodiphenyldichloroethylene (DDE): a meta-analysis within 12 European Birth Cohorts. Environ Health Perspect (2011) 1.84
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics (2006) 1.80
Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis (2002) 1.73
Association between mercury concentrations in blood and hair in methylmercury-exposed subjects at different ages. Environ Res (2004) 1.59
Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. Genes Chromosomes Cancer (2008) 1.54
The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics (2011) 1.52
Cardiac autonomic activity in methylmercury neurotoxicity: 14-year follow-up of a Faroese birth cohort. J Pediatr (2004) 1.49
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol (2008) 1.48
The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics (2010) 1.44
Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol (2010) 1.44
Balancing the benefits of n-3 polyunsaturated fatty acids and the risks of methylmercury exposure from fish consumption. Nutr Rev (2011) 1.41
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell (2011) 1.40
Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol (2014) 1.38
Negative confounding in the evaluation of toxicity: the case of methylmercury in fish and seafood. Crit Rev Toxicol (2008) 1.34
Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes. Breast Cancer Res (2007) 1.30
CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol (2012) 1.29
Concentrations of polybrominated diphenyl ethers, polychlonnated biphenyls, and polychlorobiphenylols in serum from pregnant Faroese women and their children 7 years later. Environ Sci Technol (2005) 1.27
Umbilical cord mercury concentration as biomarker of prenatal exposure to methylmercury. Environ Health Perspect (2005) 1.27
Serum polychlorinated biphenyl and organochlorine insecticide concentrations in a Faroese birth cohort. Chemosphere (2005) 1.27
Economic benefits of methylmercury exposure control in Europe: monetary value of neurotoxicity prevention. Environ Health (2013) 1.26
Genetic polymorphism and toxicology--with emphasis on cytochrome p450. Toxicol Sci (2010) 1.26
Disruption of the ASTN2/TRIM32 locus at 9q33.1 is a risk factor in males for autism spectrum disorders, ADHD and other neurodevelopmental phenotypes. Hum Mol Genet (2013) 1.26
Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk. Cancer Epidemiol Biomarkers Prev (2012) 1.26
The importance of cycling of blood alcohol levels in the pathogenesis of experimental alcoholic liver disease in rats. Gastroenterology (2002) 1.24
Attenuated growth of breast-fed children exposed to increased concentrations of methylmercury and polychlorinated biphenyls. FASEB J (2003) 1.21
Hydroxylated PCB metabolites and PCBs in serum from pregnant Faroese women. Environ Health Perspect (2002) 1.21
Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos (2003) 1.20
Improving breast cancer survival analysis through competition-based multidimensional modeling. PLoS Comput Biol (2013) 1.20
Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med (2008) 1.20
3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochem Biophys Res Commun (2005) 1.19
Impact of dietary exposure to food contaminants on the risk of Parkinson's disease. Neurotoxicology (2008) 1.19
Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res (2010) 1.18
Allergy and sensitization during childhood associated with prenatal and lactational exposure to marine pollutants. Environ Health Perspect (2010) 1.17
Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am J Epidemiol (2006) 1.17
Features of 5'-splice-site efficiency derived from disease-causing mutations and comparative genomics. Genome Res (2007) 1.16
Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun (2005) 1.15
ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet (2008) 1.15
The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics (2002) 1.14
Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis (2013) 1.14
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol (2007) 1.13
The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives. Methods Mol Biol (2006) 1.13
Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol (2006) 1.13
CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer (2003) 1.13
A retrospective study of PBDEs and PCBs in human milk from the Faroe Islands. Environ Health (2005) 1.11
Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers (2002) 1.11
Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci (2010) 1.11
Combining gene signatures improves prediction of breast cancer survival. PLoS One (2011) 1.11
Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos (2009) 1.10
Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol Oncol (2009) 1.10
Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genomics (2014) 1.09
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol (2008) 1.08
Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol (2007) 1.08
Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. Free Radic Biol Med (2005) 1.08
Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases. Cell Signal (2005) 1.07
Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biol (2014) 1.07
NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations. Mol Cancer (2010) 1.06
Cytokine and chemokine expression associated with steatohepatitis and hepatocyte proliferation in rats fed ethanol via total enteral nutrition. Exp Biol Med (Maywood) (2008) 1.06
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer (2010) 1.05
Heterozygous loss-of-function variants in CYP1B1 predispose to primary open-angle glaucoma. Invest Ophthalmol Vis Sci (2009) 1.05
Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. J Biotechnol (2009) 1.05
Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol (2003) 1.05
The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol (2008) 1.04
Different structural requirements of the ligand binding domain of the aryl hydrocarbon receptor for high- and low-affinity ligand binding and receptor activation. Mol Pharmacol (2004) 1.04
Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control (2003) 1.04
Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. Genome Biol (2013) 1.04
Genetic variation in putative regulatory loci controlling gene expression in breast cancer. Proc Natl Acad Sci U S A (2006) 1.03
Fatigued breast cancer survivors and gene polymorphisms in the inflammatory pathway. Brain Behav Immun (2011) 1.03
Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer (2013) 1.02
Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci (2011) 1.02
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun (2006) 1.02
Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. BMC Med Genomics (2011) 1.02
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics (2006) 1.02
Novel extrahepatic cytochrome P450s. Toxicol Appl Pharmacol (2005) 1.01
3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. Toxicol Sci (2013) 1.01
GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Res (2008) 1.01
Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme. Hum Mutat (2008) 1.00
Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J (2009) 1.00
Gene expression analyses in breast cancer epidemiology: the Norwegian Women and Cancer postgenome cohort study. Breast Cancer Res (2008) 0.99
Analyzing cancer samples with SNP arrays. Methods Mol Biol (2012) 0.99
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol (2011) 0.98